Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Measom

Psychiatry Slc, UT Medical Doctor

NPI 1861479701 CMS profile 986129

265 E 100 S Ste 250, Slc, UT 84111

Open in the dashboard

General payments

$2,174,251

3,146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Measom of Slc, UT is reported in the CMS Open Payments database as having received $2,174,251 across 3,146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $348,227 490
2024 General $376,076 524
2023 General $335,453 466
2022 General $319,150 442
2021 General $257,595 371
2020 General $131,551 213
2019 General $406,199 640

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Measom
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Michael Measom were reported at $348,227. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Michael Measom Psychiatry median Middle half National median
2019 $406,199 $184 $59–$605 $163
2020 $131,551 $119 $36–$372 $114
2021 $257,595 $143 $43–$576 $132
2022 $319,150 $153 $50–$590 $149
2023 $335,453 $170 $56–$651 $160
2024 $376,076 $179 $57–$673 $164
2025 $348,227 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $620,197 974 payments
  2. Alkermes, Inc. $507,146 664 payments
  3. Neurocrine Biosciences, Inc. $380,249 414 payments
  4. Axsome Therapeutics, Inc. $176,069 216 payments
  5. AbbVie, Inc. $122,711 234 payments
  6. Janssen Pharmaceuticals, Inc $103,925 170 payments
  7. Vanda Pharmaceuticals Inc. $82,051 128 payments
  8. Teva Pharmaceuticals USA, Inc. $76,484 85 payments
  9. Eisai Inc. $22,580 46 payments
  10. Idorsia Pharmaceuticals US Inc $21,221 33 payments
  11. Other $61,619 182 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,602,051 589 payments
  2. Travel and Lodging $253,334 1,405 payments
  3. Consulting Fee $188,508 90 payments
  4. Honoraria $83,130 29 payments
  5. Food and Beverage $46,883 1,024 payments
  6. Education $345 9 payments
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $379,335 608 payments
  2. REXULTI $255,265 416 payments
  3. VIVITROL $246,381 311 payments
  4. INGREZZA $238,084 246 payments
  5. Auvelity $173,541 213 payments
  6. ABILIFY ASIMTUFII $168,069 248 payments
  7. LYBALVI Cns $161,840 219 payments
  8. LYBALVI Cns $149,487 205 payments
  9. LYBALVI Cns $149,211 197 payments
  10. LYBALVI Cns $149,211 197 payments
  11. Other $1,151,729 1,745 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

61

Median for Psychiatry: 574

Drug cost

$13,102

Median for Psychiatry: $27,624

Branded share of claims

18%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 11 $11,821
Lamotrigine Generic 27 $912
Lithium Carbonate Generic 23 $369

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
$78,717 — —
VIVITROL
$46,771 — —
ABILIFY MAINTENA
$39,052 — —
ABILIFY ASIMTUFII
$37,628 — —
VRAYLAR
$36,634 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

3,146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record